SCHEMBL1098674

SCHEMBL1098674

O=S(=O)(c1ccccc1)N(Cc1ccc(OC(F)(F)F)cc1)c1cc2ccccc2s1

nearest known ligand 0.54

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 1/20 0.54
TRPM8 Q7Z2W7 18/20 0.54
CNR2 P34972 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1099967 0.90 NR3C1 (0.50) NR3C1TRPM8
SCHEMBL1098696 0.86 PGR (0.52) NR3C1CNR2
SCHEMBL1099311 0.85 ALDH1A1 (0.48) NR3C1TRPM8CNR2
SCHEMBL10280383 0.85 TRPM8 (0.47) NR3C1TRPM8
SCHEMBL2060609 0.83 TRPM8 (0.43) NR3C1TRPM8CNR2
SCHEMBL13262136 0.83 TRPM8 (0.42) NR3C1TRPM8CNR2
SCHEMBL2061062 0.83 TRPM8 (0.44) NR3C1TRPM8
SCHEMBL1098611 0.83 TRPM8 (0.46) NR3C1TRPM8
SCHEMBL1097602 0.82 PKM (0.54) NR3C1CNR2
SCHEMBL2060913 0.80 TRPM8 (0.45) TRPM8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9434711-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2016-09-06 US disclosed
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-10-23 US disclosed
US-8809327-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2014-08-19 US disclosed
EP-2183239-B1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2012-08-22 EP disclosed
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS BRANUM SHAWN T (US) 2012-07-26 US disclosed
US-8153682-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2012-04-10 US disclosed
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 NR3C1 2769/4885TRPM8 1/4885CNR2 127/4885
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 NR3C1 2769/4885TRPM8 1/4885CNR2 127/4885
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 NR3C1 2769/4885TRPM8 1/4885CNR2 127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.